Innovent Biologics, Inc. (1801.HK) HKSE

Currency In HKD

AD

Valuation

Market Cap118.55B
Enterprise Value104.02B
P/E Ratio154.67
PEG Ratio0.18
Price/Sales Ratio10.28
Price/Book Ratio6.81
Enterprise/Revenue9.17
Enterprise/EBITDA91.23

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterDecember 31, 2025

Profitability

Profit Margin0.06
Operating Margin0.06
AD

Management Effectiveness

Return On Assets0.02
Return On Equity0.05

Income Statement

Revenue13.04B
Revenue/Share7.62
Gross Profit10B
EBITDA1.31B
Net Income813.57M
Diluted EPS0.47

Balance Sheet

Total Cash18.24B
Total Cash/Share10.65
Total Debt2.82B
Total Debt/Equity0.15
Current Ratio2.62
Book Value Per Share11.78

Price History

52-Week Change8.66
52-Week High109.1
52-Week Low69.55
Moving Average 50 Days81.7
Moving Average 200 Days85.48

Statistics

Average Volume13.95M
Shares Outstanding1.74B
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A
AD